Joshua Silverwood

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in Parkinson’s disease.

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability progression.

Beigene has chosen to scrap ociperlimab after analysis found the lung cancer drug wouldn't its endpoint in extending overall survival.

Initial results from the ongoing trial saw one patient achieving a complete response in the trial combining Tovecimig with paclitaxel.

Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, DM-101PX.

Three patients living with hypertrophic cardiomyopathy have had their disease classification downgraded following a single dose of TN-201

AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy.

Results from the company’s trial of 3,500 patients found that disease burden was higher in men but women were at higher risk of MACE.

The company’s Phase II IMPACT-1 trial found treatment with TSND-201 was generally safe and well tolerated in PTSD patients.

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in chemotherapy.

Results from the company’s Phase II trial also saw PL8177 elicit a clinical response in 77% of ulcerative colitis patients.

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

The results suggest that IGC-AD1 may decrease the frequency and severity of sleep disturbances and night time behaviours.

Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five Duchenne trials in 2025.

The randomised trial saw more than half of patients dosed with Sunosi achieving clinical response to the therapy used to treat narcolepsy.

Mural Oncology’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other options.

The AUR87A study found that urine collected biomarkers could accurately predict recurrence of kidney cancer in post-surgery patients.

Opthia could owe $1bn to investors amid sozinibercept trial failure

iECURE previously announced that the first patient dosed with ECUR-506 for OTC deficiency achieved a complete clinical response.